Welcome to our dedicated page for GRI Bio news (Ticker: $GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GRI Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GRI Bio's position in the market.
GRI Bio announced positive preclinical data for its lead program GRI-0621 in treating Idiopathic Pulmonary Fibrosis (IPF). The data, presented at the 2024 ATS International Conference, showed that GRI-0621 significantly reduced fibrosis and lung inflammation in a mouse model by inhibiting type 1 invariant Natural Killer T (iNKT) cell activity. The company is advancing to a Phase 2a biomarker study, with interim data expected in Q3 2024 and topline results in Q4 2024. This study will evaluate the safety, tolerability, and biomarker effects of GRI-0621 in IPF patients.
GRI-0621's mechanism involves inhibiting iNKT cells, which are pivotal in the early stages of fibrotic disease. Existing IPF treatments are and come with significant side effects, making GRI-0621 a promising candidate. GRI Bio aims to leverage the 505(b)(2) regulatory pathway to accelerate the drug's development.
GRI Bio, a biotechnology company listed on NASDAQ under the ticker GRI, will present at Alliance Global Partner’s 2024 Healthcare Company Showcase. The event is scheduled for May 21, 2024, at 2:40 PM ET. The company specializes in developing Natural Killer T (NKT) cell modulators to treat inflammatory, fibrotic, and autoimmune diseases. Marc Hertz, PhD, CEO of GRI Bio, will participate in a live webcast fireside chat. This event can be accessed through the Investors section on GRI Bio's website.
GRI Bio, Inc. reported its first quarter financial results for 2024, highlighting the progress of their lead programs GRI-0621 for Idiopathic Pulmonary Fibrosis and GRI-0803 for Systemic Lupus Erythematosus. The company is focused on advancing innovative NKT cell modulators for various diseases. The financial results showed a net loss of $1.9 million, with research and development expenses increasing compared to the previous year. GRI Bio closed a public offering in February 2024, raising $5.5 million to support ongoing operations.
GRI Bio, Inc. (NASDAQ: GRI) announced that its abstracts have been accepted for presentation at the 14th International Congress on Autoimmunity. The company will discuss innovative treatments for inflammatory, fibrotic, and autoimmune diseases, with presentations by Chief Scientific Officer, Vipin Kumar Chaturvedi. The event will take place in Ljubljana, Slovenia on May 17-20, 2024.
